Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("HIBBERD, Patricia L")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 51

  • Page / 3
Export

Selection :

  • and

Challenges in the design of antibiotic equivalency studies: The multicenter equivalency study of oral amoxicillin versus injectable penicillin in children aged 3-59 months with severe pneumoniaHIBBERD, Patricia L; PATEL, Archana.Clinical infectious diseases. 2004, Vol 39, Num 4, pp 526-531, issn 1058-4838, 6 p.Article

Probiotic Foods and Drugs : Impact of US Regulatory Status on Design of Clinical TrialsHIBBERD, Patricia L; DAVIDSON, Lisa.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S137-S140, SUP2Conference Paper

The Internet and psychoactive substance use among innovative drug usersBOYER, Edward W; SHANNON, Michael; HIBBERD, Patricia L et al.Pediatrics (Evanston). 2005, Vol 115, Num 2, pp 302-305, issn 0031-4005, 4 p., 1Article

Probiotics for Prevention of Antibiotic-associated DiarrheaIDIT DORON, Shira; HIBBERD, Patricia L; GORBACH, Sherwood L et al.Journal of clinical gastroenterology. 2008, Vol 42, Num 6, issn 0192-0790, S58-S63, SUP2Conference Paper

Developing Probiotics as Food and Drugs: Scientific and Regulatory ChallengesHIBBERD, Patricia L; HOFFMAN, Freddie Ann; HEIMBACH, James T et al.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, 101 p., SUP2Conference Proceedings

Is maternal age at delivery related to childhood food allergy?DIOUN, Anahita F; HARRIS, Sion Kim; HIBBERD, Patricia L et al.Pediatric allergy and immunology. 2003, Vol 14, Num 4, pp 307-311, issn 0905-6157, 5 p.Article

Development of Probiotics as Biologic DrugsHOFFMAN, Freddie Ann.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S125-S127, SUP2Conference Paper

Product Development of Probiotics as Biological DrugsSUTTON, Ann.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S128-S132, SUP2Conference Paper

Health-Benefit Claims for Probiotic ProductsHEIMBACH, James T.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S122-S124, SUP2Conference Paper

Mechanisms of Action of ProbioticsWALKER, W. Allan.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S87-S91, SUP2Conference Paper

Preclinical Testing in the Development of Probiotics : A Regulatory Perspective with Bacillus Strains as an ExampleSOROKULOVA, Iryna.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S92-S95, SUP2Conference Paper

Computerized recruiting for clinical trials in real timeWEINER, Debra L; BUTTE, Atul J; HIBBERD, Patricia L et al.Annals of emergency medicine. 2003, Vol 41, Num 2, pp 242-246, issn 0196-0644, 5 p.Conference Paper

Business Considerations in the Development of ProbioticsHOFFMAN, Freddie Ann.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S141-S143, SUP2Conference Paper

Role of Probiotics Stakeholders in Future Research and Policy on Probiotics Use in the United StatesKLEIN, Marguerite; DWYER, Johanna.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S144-S151, SUP2Conference Paper

The US Food and Drug Administration and Probiotics : Regulatory CategorizationDEGNAN, Frederick H.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S133-S136, SUP2Conference Paper

Clinical Research on Probiotics : The Interface between Science and RegulationTAMAYO, Carmen.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S101-S103, SUP2Conference Paper

How Science Will Help Shape Future Clinical Applications of ProbioticsREID, Gregor.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S62-S66, SUP2Conference Paper

Probiotic Formulations and Applications, the Current Probiotics Market, and Changes in the Marketplace : A European PerspectiveSAXELIN, Maija.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S76-S79, SUP2Conference Paper

Regulation of Probiotic Substances as Ingredients in Foods : Premarket Approval or Generally Recognized as Safe NotificationMATTIA, Antonia; MERKER, Robert.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S115-S118, SUP2Conference Paper

Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancerALEXANDER, Sarah W; WADE, Kelly C; HIBBERD, Patricia L et al.Journal of pediatric hematology/oncology. 2002, Vol 24, Num 1, pp 38-42, issn 1077-4114Article

Current Marketplace for Probiotics : A Japanese PerspectiveAMAGASE, Harunobu.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S73-S75, SUP2Conference Paper

Environmental Assessment Requirements for Live Biological DrugsSUTTON, Ann.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S112-S114, SUP2Conference Paper

Probiotics : Definition, Sources, Selection, and UsesSANDERS, Mary Ellen.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S58-S61, SUP2Conference Paper

Probiotics in the United StatesVANDERHOOF, Jon A; YOUNG, Rosemary.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S67-S72, SUP2Conference Paper

The Safety of ProbioticsSNYDMAN, David R.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S104-S111, SUP2Conference Paper

  • Page / 3